(Q82442592)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21073988%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Economic evaluation of infant and adolescent hepatitis B vaccination in the UK (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21073988%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

M Ruby Siddiqui

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21073988%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Nigel Gay

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21073988%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

10 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21073988%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21073988%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21073988%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21073988%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

466-475

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21073988%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus. The major etiology of hepatocellular carcinoma

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

The influence of age on the development of the hepatitis B carrier state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Epidemiology of hepatitis B infection in North America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

The prevalence of hepatitis B infection in adults with no recognized increased risk of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Failure to deliver hepatitis B vaccine: confessions from a genitourinary medicine clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Harm reduction measures and injecting inside prison versus mandatory drugs testing: results of a cross sectional anonymous questionnaire survey. The European Commission Network on HIV Infection and Hepatitis in Prison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Obstacles to hepatitis B vaccine uptake by health care staff

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Poor uptake of hepatitis B immunization amongst hospital-based health care staff

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Commentary: antenatal screening and targeting should be sufficient in some countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Vaccination against hepatitis B virus in highly endemic areas: waning vaccine-induced immunity and the need for booster doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Hepatitis B incidence among South Asian children in England and Wales: implications for immunisation policy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Increased risk for lethal forms of liver disease among HBsAg-positive blood donors in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

The first 2 years of the Gambian National Cancer Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Epidemiology of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Costs of running a universal adolescent hepatitis B vaccination programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

National Institute for Clinical Excellence and its value judgments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Model based analysis of hepatitis B vaccination strategies in the Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine: estimating cost-effectiveness using decision analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

An economic evaluation of universal vaccination against hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Seroepidemiology of hepatitis B virus in the Philippines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Promotion of murine hepatocarcinogenesis by testosterone is androgen receptor-dependent but not cell autonomous

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Hepatocellular carcinoma in Italian patients with cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

NIH conference. Hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Impact of hepatitis B and C virus on kidney transplantation outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Acute hepatitis B infection in England and Wales: 1985–96

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Control of hepatitis B in the United Kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Are booster immunisations needed for lifelong hepatitis B immunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Epidemiology and natural history of hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

Cost of acute hepatitis B infection in Swedish adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

The Liver Histology and Frequency of Clearance of the Hepatitis B Surface Antigen (HBsAg) in Chronic Carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.075

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.10.075

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21073988%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference